


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:30Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406933" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406933</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmjo</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="pmc-domain-id">1609</journal-id><journal-id journal-id-type="pmc-domain">bmjo</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406933</article-id><article-id pub-id-type="pmcid-ver">PMC12406933.1</article-id><article-id pub-id-type="pmcaid">12406933</article-id><article-id pub-id-type="pmcaiid">12406933</article-id><article-id pub-id-type="pmid">40897484</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2025-101442</article-id><article-id pub-id-type="publisher-id">bmjopen-2025-101442</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Protocol</subject></subj-group><subj-group subj-group-type="heading"><subject>Paediatrics</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1719</subject><subject>1506</subject></subj-group></article-categories><title-group><article-title>Study protocol: neonatal colonisation and infection with Ureaplasma in very immature preterm infants born &lt;29 weeks of gestation (NEO-CONSCIOUS) &#8211; a prospective multicentre study assessing early life colonisation rates and potentially associated adverse outcomes</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2158-0222</contrib-id><name name-style="western"><surname>Glaser</surname><given-names initials="K">Kirsten</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rittenschober-B&#246;hm</surname><given-names initials="J">Judith</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Humberg</surname><given-names initials="A">Alexander</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stichtenoth</surname><given-names initials="G">Guido</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Butzer</surname><given-names initials="S">Sarina</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mehler</surname><given-names initials="K">Katrin</given-names></name><xref rid="aff6" ref-type="aff">6</xref><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kipfm&#252;ller</surname><given-names initials="F">Florian</given-names></name><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>K&#246;stlin-Gille</surname><given-names initials="N">Natascha</given-names></name><xref rid="aff9" ref-type="aff">9</xref><xref rid="aff10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gille</surname><given-names initials="C">Christian</given-names></name><xref rid="aff10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kick</surname><given-names initials="A">Andrea</given-names></name><xref rid="aff11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dornis</surname><given-names initials="D">Diana</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Henrich</surname><given-names initials="B">Birgit</given-names></name><xref rid="aff12" ref-type="aff">12</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4628-9052</contrib-id><name name-style="western"><surname>Farr</surname><given-names initials="A">Alex</given-names></name><xref rid="aff13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>H&#228;rtel</surname><given-names initials="C">Christoph</given-names></name><xref rid="aff14" ref-type="aff">14</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9678-326X</contrib-id><name name-style="western"><surname>Silwedel</surname><given-names initials="C">Christine</given-names></name><xref rid="aff14" ref-type="aff">14</xref><xref rid="cor1" ref-type="corresp"/></contrib><aff id="aff1"><label>1</label><institution>Division of Neonatology, Department of Women&#8217;s and Children&#8217;s Health, University of Leipzig Medical Center</institution>, <addr-line content-type="city">Leipzig</addr-line>, <country>Germany</country></aff><aff id="aff2"><label>2</label><institution>Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Department of Pediatrics and Adolescent Medicine, Comprehensive Centre for Pediatrics, Medical University of Vienna</institution>, <addr-line content-type="city">Vienna</addr-line>, <country>Austria</country></aff><aff id="aff3"><label>3</label><institution content-type="department">Department of Neonatology</institution>, <institution>Women's and Children's Clinic, Kepler University Hospital</institution>, <addr-line content-type="city">Linz</addr-line>, <country>Austria</country></aff><aff id="aff4"><label>4</label><institution content-type="department">Department of Pediatrics</institution>, <institution>University Hospital M&#252;nster</institution>, <addr-line content-type="city">M&#252;nster</addr-line>, <country>Germany</country></aff><aff id="aff5"><label>5</label><institution content-type="department">Department of Pediatrics</institution>, <institution>University Hospital of L&#252;beck</institution>, <addr-line content-type="city">L&#252;beck</addr-line>, <country>Germany</country></aff><aff id="aff6"><label>6</label><institution>University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Pediatrics, Division of Pediatric Infectious Diseases</institution>, <addr-line content-type="city">K&#246;ln</addr-line>, <country>Germany</country></aff><aff id="aff7"><label>7</label><institution>University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Pediatrics, Division of Neonatology</institution>, <addr-line content-type="city">K&#246;ln</addr-line>, <country>Germany</country></aff><aff id="aff8"><label>8</label><institution>Department of Neonatology and Pediatric Intensive Care Medicine, University Medical Center Mannheim, University of Heidelberg</institution>, <addr-line content-type="city">Mannheim</addr-line>, <country>Germany</country></aff><aff id="aff9"><label>9</label><institution>Department of Neonatology, T&#252;bingen University Children&#8217;s Hospital</institution>, <addr-line content-type="city">T&#252;bingen</addr-line>, <country>Germany</country></aff><aff id="aff10"><label>10</label><institution>Department of Neonatology, Heidelberg University, Medical Faculty</institution>, <addr-line content-type="city">Heidelberg</addr-line>, <country>Germany</country></aff><aff id="aff11"><label>11</label><institution>Klinik Hallerwiese-Cnopf&#8217;sche Kinderklinik, Clinic for Neonatology and Paediatric Intensive Care</institution>, <addr-line content-type="city">N&#252;rnberg</addr-line>, <country>Germany</country></aff><aff id="aff12"><label>12</label><institution>Institute of Medical Microbiology and Hospital Hygiene, University Clinic of Heinrich-Heine University D&#252;sseldorf</institution>, <addr-line content-type="city">D&#252;sseldorf</addr-line>, <country>Germany</country></aff><aff id="aff13"><label>13</label><institution>Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-Maternal Medicine, Medical University of Vienna, and Comprehensive Center for Pediatrics (CCP), Medical University of Vienna</institution>, <addr-line content-type="city">Vienna</addr-line>, <country>Austria</country></aff><aff id="aff14"><label>14</label><institution>University Hospital W&#252;rzburg, University of W&#252;rzburg, Department of Pediatrics</institution>, <addr-line content-type="city">W&#252;rzburg</addr-line>, <country>Germany</country></aff></contrib-group><author-notes><fn><p>Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></fn><fn fn-type="COI-statement" id="fn4"><p>None declared.</p></fn><corresp id="cor1">Dr Christine Silwedel; <email xlink:href="silwedel_c@ukw.de">silwedel_c@ukw.de</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>9</month><year>2025</year></pub-date><volume>15</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496158</issue-id><elocation-id>e101442</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&#160;<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="bmjopen-15-9.pdf"/><self-uri xlink:title="pdf" xlink:href="bmjopen-15-9.pdf"/><abstract><title>Abstract</title><sec><title>Introduction</title><p>Preterm infants, particularly those born before 29 weeks of gestation, are at increased risk of developing bronchopulmonary dysplasia (BPD) and other complications of prematurity. Substantial evidence suggests that respiratory tract colonisation with <italic toggle="yes">Ureaplasma</italic> species significantly contributes to pulmonary inflammation, impaired lung function and subsequent lung disease especially in very immature infants. Moreover, <italic toggle="yes">Ureaplasma</italic> exposure has been implicated in the pathogenesis of other inflammation-related sequelae of prematurity. Although representing a potentially actionable risk factor for adverse short-term and long-term neonatal outcome, controversies on <italic toggle="yes">Ureaplasma</italic>-associated morbidity remain and recommendations for screening practices in preterm infants are missing. The NEO-CONSCIOUS (Neonatal Colonisation and Infection with <italic toggle="yes">Ureaplasma</italic> in very immature preterm infants born &lt;29 weeks of gestation) study aims to assess the incidence of <italic toggle="yes">Ureaplasma</italic> colonisation and infection in very preterm infants at high risk of adverse outcome, the extent of potentially accompanying inflammation and the impact on short-term and long-term morbidity.</p></sec><sec><title>Methods and analysis</title><p>This is a prospective observational multicentre study being conducted in level III neonatal intensive care units in Germany and Austria. In total, 400 infants born before 29 weeks of gestation are screened for <italic toggle="yes">Ureaplasma</italic> colonisation immediately after birth. In addition, biomarkers of systemic inflammation are determined on day 1 and day 28. The study infants are followed up until discharge and at 2 years corrected age. The primary outcome BPD and/or death is assessed at 36 weeks postmenstrual age. Secondary outcomes include systemic inflammation, secondary infections, intraventricular haemorrhage, periventricular leukomalacia, necrotising enterocolitis, retinopathy of prematurity and neurodevelopmental outcome at 24 months corrected age.</p></sec><sec><title>Ethics and dissemination</title><p>The study has been approved by the ethics committees in W&#252;rzburg and Leipzig and the local ethics committees of all participating centres. Results will be disseminated through peer-reviewed international publications and conferences. The study is registered with the German Clinical Trials Register, ID DRKS00033001.</p></sec><sec><title>Trial registration number</title><p>German Clinical Trials Register (DRKS00033001).</p></sec></abstract><kwd-group><kwd>NEONATOLOGY</kwd><kwd>PAEDIATRICS</kwd><kwd>Pulmonary Disease</kwd><kwd>Inflammation</kwd><kwd>MICROBIOLOGY</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Roland Ernst Stiftung f&#252;r Gesundheitswesen</institution></institution-wrap></funding-source><award-id>03/23 (to Kirsten Glaser and Christine Silwedel)</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title></caption><list list-type="bullet" list-content="ul"><list-item><p>This is a well-powered, prospective, observational multicentre study assessing the incidence of early life <italic toggle="yes">Ureaplasma</italic> colonisation in very preterm infants as well as its association with the development of chronic lung disease and other complications of prematurity.</p></list-item><list-item><p>This study focuses on a select cohort of high-risk preterm infants starting from 22+0 weeks of gestation, who are often under-represented in previous studies.</p></list-item><list-item><p>The use of state-of-the-art diagnostics for early and standardised <italic toggle="yes">Ureaplasma</italic> screening, combined with longitudinal assessment of systemic inflammation and inclusion of both short-term and long-term outcome, strengthens the comprehensiveness of the study.</p></list-item><list-item><p>The prospective multicentre design across level III neonatal intensive care units enhances the generalisability and robustness of the findings; however, variability in clinical management and diagnostic practices across multiple centres may introduce heterogeneity that could affect the consistency of outcome assessments.</p></list-item><list-item><p>This study may help to close a gap in current knowledge by addressing the link between <italic toggle="yes">Ureaplasma</italic> colonisation, systemic inflammation and adverse outcome in preterm neonates, using a comprehensive approach in exploring inflammation-driven neonatal morbidity.</p></list-item></list></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p> Advances in perinatal and neonatal care have substantially improved survival rates even among very immature preterm infants. Yet, the incidence of chronic conditions such as bronchopulmonary dysplasia (BPD) and neurological impairments remains high in this vulnerable cohort, and preterm birth still yields a significant impact on neonatal outcome.<xref rid="R1" ref-type="bibr"><sup>1 2</sup></xref></p><p><italic toggle="yes">Ureaplasma</italic> species (spp.) are common bacterial colonisers of the adult urogenital tract. Yet, in pregnancy, <italic toggle="yes">Ureaplasma</italic> rank among the most frequently detected bacterial pathogens in the context of chorioamnionitis and preterm premature rupture of membranes and have repetitively been described as contributors to preterm birth.<xref rid="R3" ref-type="bibr"><sup>3 4</sup></xref> Furthermore, <italic toggle="yes">Ureaplasma</italic> are frequently transmitted to the infant, with highest transmission rates at low gestational ages and subsequent detection rates of up to 60% in the most immature preterm infants.<xref rid="R4" ref-type="bibr">4</xref><xref rid="R7" ref-type="bibr">7</xref> Several studies and large-scale meta-analyses have reported a significant association between BPD and preterm respiratory tract colonisation with <italic toggle="yes">Ureaplasma</italic>.<xref rid="R6" ref-type="bibr">68</xref><xref rid="R11" ref-type="bibr">11</xref> The most recent meta-analysis, published in 2024, documented a 2.3-fold risk of BPD in <italic toggle="yes">Ureaplasma-</italic>colonised preterm infants.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> However, huge controversy remains, mainly due to small overall sample sizes and heterogeneities across studies concerning sampling and diagnostic methods. Most importantly, the majority of available investigations spans a period of more than 30 years, encompassing subsequent changes in neonatal practice, in <italic toggle="yes">Ureaplasma</italic> diagnostics and BPD definition.</p><p>It is worth mentioning that some evidence furthermore indicates an association between perinatal and postnatal exposure of preterm infants to <italic toggle="yes">Ureaplasma</italic> and increased risks for other neonatal morbidities. <italic toggle="yes">Ureaplasma</italic> infection might contribute to intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL), necrotising enterocolitis (NEC) and retinopathy of prematurity (ROP), and might modulate inflammatory conditions and predispose to secondary infections, and may furthermore cause long-term developmental impairment.<xref rid="R12" ref-type="bibr">12</xref><xref rid="R14" ref-type="bibr">14</xref></p><p>This necessitates a better understanding of <italic toggle="yes">Ureaplasma</italic> as potentially actionable risk factor in preterm infants as well as their contributing role in adverse neonatal inflammation and sustained inflammatory responses that promote BPD and many other complications of prematurity.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref></p><p>To close the existing gap of knowledge and to address the lack of well-powered clinical studies, the present NEO-CONSCIOUS (Neonatal Colonisation and Infection with <italic toggle="yes">Ureaplasma</italic> in very immature preterm infants born &lt;29 weeks of gestation) study will (i) evaluate the incidence of early life <italic toggle="yes">Ureaplasma</italic> colonisation and infection in a cohort of very preterm infants using state-of-the-art diagnostics, (ii) assess signs of associated systemic inflammation and (iii) address any impact on short-term and long-term outcome, primarily on BPD. This study uses a prospective cohort design across multiple centres in Germany and Austria.</p></sec><sec id="s2"><title>Methods and analysis</title><sec id="s2-1"><title>Study design</title><p>This is a prospective, multicentre, observational study assessing the incidence of neonatal <italic toggle="yes">Ureaplasma</italic> colonisation and infection and its potential association with short-term and long-term outcomes in a cohort of very immature preterm infants born before 29 completed weeks of gestation (<xref rid="F1" ref-type="fig">figure 1</xref>).</p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><title>NEO-CONSCIOUS (Neonatal Colonisation and Infection with <italic toggle="yes">Ureaplasma</italic> in very immature preterm infants born &lt;29 weeks of gestation) study overview. Figure created in biorender.com.</title></caption><graphic position="float" orientation="portrait" xlink:href="bmjopen-15-9-g001.jpg"/></fig></sec><sec id="s2-2"><title>Objectives</title><p>The study&#8217;s primary objective is to investigate whether extremely preterm infants born &lt;29 weeks of gestation with perinatal <italic toggle="yes">Ureaplasma</italic> colonisation or infection bear an increased risk of developing BPD compared with those without <italic toggle="yes">Ureaplasma</italic> colonisation.</p><p>Secondary objectives of the NEO-CONSCIOUS study are to assess whether <italic toggle="yes">Ureaplasma</italic>-positive infants present with postnatal systemic inflammation and/or persistent inflammatory responses more frequently than <italic toggle="yes">Ureaplasma</italic>-negative infants. Moreover, as secondary objectives, this study will evaluate the potential association between <italic toggle="yes">Ureaplasma</italic> colonisation and the occurrence of non-pulmonary complications and investigate the impact of perinatal <italic toggle="yes">Ureaplasma</italic> colonisation on long-term neurodevelopmental outcome at 24 months corrected age.</p></sec><sec id="s2-3"><title>Setting</title><p>NEO-CONSCIOUS is conducted in tertiary level neonatal intensive care units in Germany and Austria, with enrolment planned from November 2024 to October 2026. The study aims at a sample size of 400 preterm infants born &lt;29 weeks of gestational age.</p></sec><sec id="s2-4"><title>Inclusion criteria</title><list list-type="order" list-content="ol"><list-item><p>Preterm infants born at &lt;29+0 weeks of gestational age (including multiple births).</p></list-item><list-item><p>Inborn infants born at the participating site.</p></list-item><list-item><p>Written informed consent from parents/guardians obtained within the first 24 hours after birth.</p></list-item></list></sec><sec id="s2-5"><title>Exclusion criteria</title><list list-type="order" list-content="ol"><list-item><p>Major congenital malformations.</p></list-item><list-item><p>Outborn preterm infants transferred from other hospitals.</p></list-item></list></sec><sec id="s2-6"><title>Primary and secondary outcomes</title><p>The primary outcome of this study is the incidence of BPD and/or death before 36 weeks postmenstrual age (PMA, <xref rid="B1" ref-type="boxed-text">box 1</xref>). BPD<sub>2001</sub> is defined according to Jobe and Bancalari as requirement of oxygen therapy for at least 28 days and classified as mild, moderate or severe based on the level of supplemental oxygen administered at 36 weeks&#8217; PMA, according to standard clinical care.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> This allows our data to be compared with the results of previous studies. For additional exploratory analysis, we will further assess the outcome of BPD<sub>2019</sub> in all study patients according to the Jensen definition based on the mode of supplemental respiratory support required at 36 weeks PMA.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> Death was defined as death prior to 36 weeks&#8217; PMA.</p><boxed-text id="B1" position="float" orientation="portrait"><label>Box 1</label><caption><title>Primary and secondary outcomes</title></caption><sec><title>Primary outcome</title><p>Bronchopulmonary dysplasia (BPD) or death before 36 weeks</p></sec><sec><title>Secondary outcomes</title><p>Perinatal and persistent inflammatory responses</p><p>Non-pulmonary complications</p><list list-type="bullet" list-content="ul"><list-item><p>Secondary bacterial infections and neonatal sepsis</p></list-item><list-item><p>Intraventricular haemorrhage (IVH)</p></list-item><list-item><p>Periventricular leukomalacia (PVL)</p></list-item><list-item><p>Necrotising enterocolitis (NEC)</p></list-item><list-item><p>Retinopathy of prematurity (ROP)</p></list-item></list><p>Neurodevelopmental outcome at 24 months corrected age</p></sec></boxed-text><p>Secondary outcomes comprise the following: the incidence of perinatal and/or persistent systemic inflammation, the rates of non-pulmonary neonatal complications including secondary bacterial infections and neonatal sepsis as well as IVH, PVL, NEC, ROP and neurodevelopmental long-term outcome (<xref rid="B1" ref-type="boxed-text">box 1</xref>). Neonatal systemic inflammation corresponds to elevated serum cytokines assessed by multianalyte immunoassay in cord blood or peripheral blood taken on day 1 of life and in blood samples taken at the age of 4&#8201;weeks. Clinical sepsis is defined by clinical and laboratory signs of infection as well as antibiotic therapy &#8805;5&#8201;days according to the criteria of the German national nosocomial infection surveillance system in preterm infants (NEO-KISS).<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> Culture-proven sepsis is defined by clinical sepsis criteria and detection of a causative pathogen in one or more blood cultures according to NEO-KISS.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> Meningitis corresponds to cerebrospinal fluid (CSF) pathogen detection and/or pathologic CSF inflammatory parameters,<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> IVH is diagnosed and classified via cranial ultrasound according to the recommendations of the German Society of Ultrasound in Medicine (DEGUM)<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> and PVL is defined as bilateral periventricular cysts at the age of &#8805;28 days.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> NEC &#8805; &#176;II is diagnosed based on clinical and radiological signs according to the modified Bell criteria or surgical confirmation.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> ROP is defined according to the German and international screening guidelines.<xref rid="R22" ref-type="bibr"><sup>22 23</sup></xref> The inclusion of definitions in the report forms ensures consistent adherence across all centres. Long-term developmental outcome is assessed at corrected 24 months, using the Bayley Scales of Infant and Toddler Development &#8211; Second/Third Edition (Bayley II/III) as well as a parental questionnaire (PARCA-R, German translation).<xref rid="R24" ref-type="bibr">24</xref><xref rid="R26" ref-type="bibr">26</xref></p></sec><sec id="s2-7"><title>Site selection, training and monitoring</title><p>Sites are selected on the basis of mutual scientific interest and personal contacts. Formal initiation visits are held on site or online and include training of the local team in study procedures and data collection. The chief investigators deliver information, ensure frequent contact and exchange along the study course, and provide necessary materials as well as guidance documents describing all study procedures in detail. Data quality will be ensured by annual on-site monitoring.</p></sec><sec id="s2-8"><title>Patient screening and consent</title><p>Screening is performed by the local team, identifying potentially eligible preterm infants prenatally or on admission. Our aim is to obtain written informed consent primarily antenatally, and no later than within the first 24 hours of life. Parents or guardians are informed about the study by the site team, and the ethically approved information sheet and parental consent form are handed over (a copy of the participant consent form is provided as an &#8216;<xref rid="SP1" ref-type="supplementary-material">online supplemental material</xref>&#8217; file). Parents/guardians are given sufficient time to read and comprehend details, and all arising questions are answered by the local study team. Written informed consent by parents or guardians is mandatory for enrolment. All infants who meet the gestational age criteria for inclusion are documented on a screening log. Potential exclusion criteria and reasons for non-participation are reported.</p></sec><sec id="s2-9"><title>Trial procedures</title><p>On birth, eligible preterm infants undergo qPCR screening for respiratory tract <italic toggle="yes">Ureaplasma</italic> colonisation (<xref rid="F2" ref-type="fig">figure 2</xref>). Moreover, study infants are screened for systemic <italic toggle="yes">Ureaplasma</italic> infection. Detected <italic toggle="yes">Ureaplasma</italic> species are differentiated according to species (<italic toggle="yes">Ureaplasma (U.) parvum</italic> and <italic toggle="yes">U. urealyticum</italic>) and genotype. Biomarkers of systemic inflammation are assessed on day 1 and day 28. Until discharge, neonatologists at the local hospitals report the clinical course, including the occurrence of BPD, secondary infections and neonatal sepsis, IVH and other complications (<xref rid="F2" ref-type="fig">figure 2</xref>). A follow-up assessment at 24 months corrected age will explore neurodevelopmental outcomes (<xref rid="F2" ref-type="fig">figure 2</xref>).</p><fig position="float" id="F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><title>Flow diagram of the NEO-CONSCIOUS (Neonatal Colonisation and Infection with <italic toggle="yes">Ureaplasma</italic> in very immature preterm infants born &lt;29 weeks of gestation) study including enrolment, sampling and follow-up strategies.</title></caption><graphic position="float" orientation="portrait" xlink:href="bmjopen-15-9-g002.jpg"/></fig></sec><sec id="s2-10"><title>Sampling and diagnostics</title><p>Nasopharyngeal or oropharyngeal swabs are obtained within 24 hours after birth using sterile diagnostic and transport swabs (UTM Copan, Italy) and stored at &#8722;20&#176;C until diagnostics. For tracheal aspirate, a sterile suction catheter is inserted into the trachea either via an endotracheal tube or preceding less invasive surfactant application. Tracheal aspirate is collected in a sterile container and stored at &#8722;20&#176;C. Umbilical cord blood samples are taken immediately after delivery using an aseptic technique after disinfection of the needle puncture site. Peripheral blood samples are taken aseptically either by venepuncture after skin disinfection or by using a central venous catheter, if available. All peripheral blood sampling will occur during routine clinical procedures and no venepuncture will be performed solely for study purposes. A 250-&#181;L whole blood sample is stored in a sterile tube at &#8722;20&#176;C until analysis. A 200-&#181;L blood sample is allowed to clot in a sterile vial, serum is separated by centrifugation and transferred into a sterile tube, which is initially stored at &#8722;20&#176;C and transferred to &#8722;80&#176;C within 96 hours until analysis.</p><p>At a central laboratory at the Institute of Microbiology at the University Hospital of D&#252;sseldorf, Germany, all pharyngeal swabs, tracheal aspirates and whole blood samples are investigated for DNA of <italic toggle="yes">U. parvum</italic> and <italic toggle="yes">U. urealyticum</italic> using a qPCR protocol described previously.<xref rid="R27" ref-type="bibr"><sup>27</sup></xref> Genotyping of <italic toggle="yes">Ureaplasma</italic> serovars will be done using an <italic toggle="yes">mba (</italic>multiple-banded antigen) gene<italic toggle="yes">-</italic>based real-time PCR approach as published previously.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref></p><p>For quantification of serum tumor necrosis factor (TNF)-&#945;, interleukin (IL)-1&#946;, IL-6, IL-8, IL-10, IL-1RA, IL-12p70 and interferon gamma induced protein (IP)-10, multianalyte immunoassays are carried out using Luminex multiplex kits and the xPonent software (Merck group, Germany) as described before.<xref rid="R7" ref-type="bibr">729</xref><xref rid="R31" ref-type="bibr">31</xref></p><p>At 24 months corrected age, participants will undergo a structured, on-site neurodevelopmental follow-up assessment using the Bayley II or III test, depending on site-specific availability and standards.<xref rid="R24" ref-type="bibr"><sup>24 25</sup></xref> Follow-up assessments will be performed by qualified and trained professionals, including paediatric psychologists, neonatologists or developmental specialists. As an additional tool to assess the neurocognitive outcome, the PARCA-R parental questionnaire is sent to the parents at the same time.<xref rid="R26" ref-type="bibr"><sup>26</sup></xref></p></sec><sec id="s2-11"><title>Data collection</title><p>All data are pseudonymised and collected using a secure, web-based electronic Case Report Form. Confidentiality is maintained in accordance with the European General Data Protection Regulation. Collected data will be monitored regularly by an independent monitoring team coordinated through the primary study centres, and queries will be raised to the participating centres in case of deficiencies. Reminders and, if needed, alternative follow-up methods, including phone interviews or electronic surveys, will promote participant retention.</p></sec><sec id="s2-12"><title>Sample size calculation</title><p>Based on the early postnatal <italic toggle="yes">Ureaplasma</italic> screening, participants are categorised into <italic toggle="yes">Ureaplasma</italic>-positive and <italic toggle="yes">Ureaplasma</italic>-negative groups. According to the results of previous studies, we estimated a <italic toggle="yes">Ureaplasma</italic> colonisation rate of around 33% of the study population.<xref rid="R7" ref-type="bibr"><sup>7 32 33</sup></xref> For the primary outcome, we presumed a BPD rate of 25% as well as an OR (BPD) of 2.2 for <italic toggle="yes">Ureaplasma</italic>-positive infants.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> Sample size calculation was conducted for a stratified design with seven strata and two groups (with/without <italic toggle="yes">Ureaplasma</italic> detection), and was based on a continuity corrected Cochran-Mantel-Haenszel Z-Test. To detect a statistically significant difference in BPD incidence between <italic toggle="yes">Ureaplasma</italic>-positive and negative groups, we anticipated a sample size of 268 infants. This calculation is based on 80% power with a 5% significance level. Calculating with a 20% risk of death before 36 weeks PMA<xref rid="R34" ref-type="bibr"><sup>34</sup></xref> and a dropout rate of 5%, the total sample size was adjusted to 400 infants. Details regarding sample size calculation for secondary outcomes are listed in <xref rid="T1" ref-type="table">table 1</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Assumed incidence rates, statistical parameters and calculated as well as adjusted sample sizes for secondary outcomes</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1"/><th valign="bottom" rowspan="1" colspan="1">Assumed incidence in infants with/without <italic toggle="yes">Ureaplasma</italic> detection</th><th valign="bottom" rowspan="1" colspan="1">&#945;</th><th valign="bottom" rowspan="1" colspan="1">&#914;</th><th valign="bottom" rowspan="1" colspan="1">Power</th><th valign="bottom" rowspan="1" colspan="1">Calculated sample size</th><th valign="bottom" rowspan="1" colspan="1">Dropout rate</th><th valign="bottom" rowspan="1" colspan="1">Adjusted sample size</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Sepsis</td><td align="left" valign="top" rowspan="1" colspan="1">25%/10%<xref rid="R7" ref-type="bibr"><sup>7</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.05</td><td align="left" valign="top" rowspan="1" colspan="1">0.2</td><td align="left" valign="top" rowspan="1" colspan="1">0.8</td><td align="left" valign="top" rowspan="1" colspan="1">213</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>224</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IVH</td><td align="left" valign="top" rowspan="1" colspan="1">24%/12%<xref rid="R40" ref-type="bibr"><sup>40</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.05</td><td align="left" valign="top" rowspan="1" colspan="1">0.2</td><td align="left" valign="top" rowspan="1" colspan="1">0.8</td><td align="left" valign="top" rowspan="1" colspan="1">345</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>363</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NEC</td><td align="left" valign="top" rowspan="1" colspan="1">15%/4%<xref rid="R41" ref-type="bibr"><sup>41</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.05</td><td align="left" valign="top" rowspan="1" colspan="1">0.2</td><td align="left" valign="top" rowspan="1" colspan="1">0.8</td><td align="left" valign="top" rowspan="1" colspan="1">228</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>240</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Severe developmental impairment</td><td align="left" valign="top" rowspan="1" colspan="1">31%/7%<xref rid="R42" ref-type="bibr"><sup>42</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.05</td><td align="left" valign="top" rowspan="1" colspan="1">0.2</td><td align="left" valign="top" rowspan="1" colspan="1">0.8</td><td align="left" valign="top" rowspan="1" colspan="1">84</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>112</bold>
</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>IVH, intraventricular haemorrhage; NEC, necrotising enterocolitis.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-13"><title>Statistical analysis</title><p>Study groups will be compared using univariable analyses, using Mann-Whitney U test for continuous and two-sided &#967;&#178; test for categorical variables. The primary endpoint (BPD and/or death at 36 weeks PMA) will be analysed using bivariate analyses (&#1061;<sup>2</sup>, Fisher&#8217;s exact test and Cram&#233;r&#8217;s V) and multivariate logistic regression models to adjust for potential confounders&#8212;considering the multihit sequence of BPD development. Secondary endpoints will be evaluated using linear and stepwise logistic multivariable regression or matched pair analysis. Covariates offered to the models will be prenatal and perinatal characteristics, that is, gestational age, birth weight, sex, singleton status, antenatal and postnatal corticosteroids, antenatal and postnatal antibiotics including macrolides, preterm premature rupture of membranes &gt;12&#8201;hours, clinical chorioamnionitis, histological chorioamnionitis, vaginal delivery, vaginal <italic toggle="yes">Ureaplasma</italic>/GBS/other bacteria/<italic toggle="yes">Candida</italic>, Apgar score, standard surfactant treatment and less invasive surfactant administration. Further covariates will be surrogate markers of a poor clinical course, including days on mechanical ventilation or continuous positive airway pressure (CPAP), inotropes in the first 24&#8201;hours, days until full enteral feeds, sepsis episodes, NEC, IVH and patent ductus arteriosus requiring treatment. Covariates will be included if significant at p&lt;0.10 in preceding analyses using &#1061;<sup>2</sup>, Fisher&#8217;s exact test and Cram&#233;r&#8217;s V, quantile-quantile (Q-Q) plots, unpaired t and Mann-Whitney U. Missing outcome data will not be imputed in the primary analysis. However, sensitivity analyses will be conducted, using the multiple imputations method to explore the potential impact of missing data on outcomes. The characteristics of participants with missing data will be compared among the groups of <italic toggle="yes">Ureaplasma</italic>-positive and <italic toggle="yes">Ureaplasma</italic>-negative infants. Analyses will be performed using the Statistical Package of Social Sciences (SPSS) software (IBM, Germany).</p></sec><sec id="s2-14"><title>Ethics, registration and dissemination</title><p>The study protocol (version 3, May 2024) has been granted ethical approval from the ethics committee of the primary study centres (W&#252;rzburg #169/23-sc, Leipzig #010/24-ek) and the local ethics committees of all participating centres. The study is registered on the German Clinical Trials Register (DRKS00033001, May 2024), where the full study protocol and a model consent form can be accessed. Sponsors are the University Hospital W&#252;rzburg and the University of Leipzig Medical Center. Full data access is restricted to the chief investigators and authorised research personnel responsible for data analysis. Any additional access will be granted only under agreements that ensure data confidentiality and adherence to ethical standards.</p><p>Findings from this study shall be disseminated through international peer-reviewed journals and national and international conferences.</p><p>With parental consent and in compliance with ethical guidelines and data protection regulations, data and biological specimens from this study may be used for ancillary studies.</p></sec><sec id="s2-15"><title>Patients and public involvement statement</title><p>Patients were not involved in the study design.</p></sec></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>BPD remains a significant burden in very preterm infants &lt;29 weeks of gestation, with a reported incidence of almost 30% in this particularly vulnerable cohort, contributing to long-term morbidity and mortality.<xref rid="R35" ref-type="bibr"><sup>35</sup></xref> Substantial evidence exists that perinatal airway colonisation with <italic toggle="yes">Ureaplasma</italic> is associated with the multifactorial pathogenesis of BPD, and infection and inflammation have long been acknowledged as contributing factors in BPD development.<xref rid="R6" ref-type="bibr">68</xref><xref rid="R37" ref-type="bibr">10 36 37</xref> Furthermore, some studies indicate that <italic toggle="yes">Ureaplasma</italic> might be implicated in other common complications of prematurity, including secondary infections, IVH and long-term developmental delay.<xref rid="R12" ref-type="bibr">12</xref><xref rid="R14" ref-type="bibr">14</xref> The multicentre NEO-CONSCIOUS trial aims to improve the understanding of the role of <italic toggle="yes">Ureaplasma</italic> spp. in the pathogenesis of BPD and other complications of prematurity. NEO-CONSCIOUS strives to overcome limitations of several available studies by screening a high-risk cohort of very preterm infants for <italic toggle="yes">Ureaplasma</italic> early in life using state-of-the-art diagnostics and correlating microbial data with biomarkers of inflammation as well as short-term outcome and long-term follow-up. Well-established qPCR diagnostics in an experienced central laboratory ensure sensitive pathogen detection and differentiation, offering insights into potential differences of <italic toggle="yes">Ureaplasma</italic> virulence at the serovar level. <italic toggle="yes">Ureaplasma</italic> qPCR screening in airway samples and blood provides a way to distinguish between colonisation and invasive infection. Two-point cytokine analysis allows for detection and monitoring of systemic inflammation in <italic toggle="yes">Ureaplasma</italic>-positive and negative study infants, which itself may contribute to adverse outcome. Comprehensive follow-up until discharge and at 24&#8201;months corrected age completes the assessment. The study&#8217;s multicentre approach allows the enrolment of an appropriate sample size of very preterm infants.</p><p>The well-powered NEO-CONSCIOUS study is therefore supposed to close the existing gap of knowledge on the pathogenicity and clinical relevance of <italic toggle="yes">Ureaplasma</italic> spp. in very immature preterm infants at high risk of adverse sequelae. Findings from the study may provide novel data on the incidence of early <italic toggle="yes">Ureaplasma</italic> colonisation and infection in very immature preterm infants and on potentially associated neonatal morbidities, especially BPD. These data might significantly impact discussions on screening practices and preventive measurements in high-risk preterm infants. The recently published results of the AZTEC (Azithromycin therapy for prevention of chronic lung disease of prematurity) trial revealed that prophylactic use of intravenous azithromycin early in life could not improve survival without moderate or severe BPD in preterm infants born &lt;30 weeks of gestation irrespective of their <italic toggle="yes">Ureaplasma</italic> colonisation status.<xref rid="R38" ref-type="bibr"><sup>38</sup></xref> However, with 148 <italic toggle="yes">Ureaplasma</italic>-positive preterm infants being enrolled and 66 of these being treated, the AZTEC trial was not sufficiently powered to investigate the impact of early life azithromycin prophylaxis in the study&#8217;s subcohort of <italic toggle="yes">Ureaplasma</italic>-positive preterm infants.<xref rid="R38" ref-type="bibr"><sup>38 39</sup></xref></p><p>While available data are incomplete and contradictory, they highlight the importance of further characterising the link between neonatal <italic toggle="yes">Ureaplasma</italic> colonisation, systemic inflammation and adverse neonatal outcomes. Ultimately, the NEO-CONSCIOUS study aims to contribute to the development of standardised screening protocols, identification and risk stratification of high-risk infants, and targeted interventions in neonatal care.</p></sec><sec sec-type="supplementary-material" id="s4"><title>Supplementary material</title><supplementary-material id="SP1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/bmjopen-2025-101442</object-id><label>online supplemental file 1</label><media xlink:href="bmjopen-15-9-s001.pdf" id="d67e920" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>We are very grateful for the expert help we received from colleagues and nurses to develop the study protocol. Moreover, we would like to acknowledge and thank for the support we received from participating hospitals and staff members. We would furthermore like to thank participating babies and parents. Artificial intelligence (ChatGPT by Open AI, San Francisco, CA, USA) was used to assist in language editing. The authors reviewed and edited all content and take full responsibility for the manuscript.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> This study is supported by the Roland Ernst Stiftung f&#252;r Gesundheitswesen, grant number 03/23 (to KG and CS).</p></fn><fn fn-type="other"><p>Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<ext-link xlink:href="https://doi.org/10.1136/bmjopen-2025-101442" ext-link-type="uri">https://doi.org/10.1136/bmjopen-2025-101442</ext-link>).</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swamy</surname><given-names>GK</given-names></name><name name-style="western"><surname>Ostbye</surname><given-names>T</given-names></name><name name-style="western"><surname>Skjaerven</surname><given-names>R</given-names></name></person-group><article-title>Association of preterm birth with long-term survival, reproduction, and next-generation preterm birth</article-title><source>JAMA</source><year>2008</year><volume>299</volume><fpage>1429</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1001/jama.299.12.1429</pub-id><pub-id pub-id-type="pmid">18364485</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>EF</given-names></name><name name-style="western"><surname>Hintz</surname><given-names>SR</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>NI</given-names></name><etal>et al</etal></person-group><article-title>Mortality, In-Hospital Morbidity, Care Practices, and 2-Year Outcomes for Extremely Preterm Infants in the US, 2013-2018</article-title><source>JAMA</source><year>2022</year><volume>327</volume><fpage>248</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.23580</pub-id><pub-id pub-id-type="pmid">35040888</pub-id><pub-id pub-id-type="pmcid">PMC8767441</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasper</surname><given-names>DC</given-names></name><name name-style="western"><surname>Mechtler</surname><given-names>TP</given-names></name><name name-style="western"><surname>Reischer</surname><given-names>GH</given-names></name><etal>et al</etal></person-group><article-title>The bacterial load of Ureaplasma parvum in amniotic fluid is correlated with an increased intrauterine inflammatory response</article-title><source>Diagn Microbiol Infect Dis</source><year>2010</year><volume>67</volume><fpage>117</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2009.12.023</pub-id><pub-id pub-id-type="pmid">20207094</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sweeney</surname><given-names>EL</given-names></name><name name-style="western"><surname>Dando</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kallapur</surname><given-names>SG</given-names></name><etal>et al</etal></person-group><article-title>The Human Ureaplasma Species as Causative Agents of Chorioamnionitis</article-title><source>Clin Microbiol Rev</source><year>2017</year><volume>30</volume><fpage>349</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1128/CMR.00091-16</pub-id><pub-id pub-id-type="pmid">27974410</pub-id><pub-id pub-id-type="pmcid">PMC5217797</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>T-J</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Frequency of ureaplasma serovars in respiratory secretions of preterm infants at risk for bronchopulmonary dysplasia</article-title><source>Pediatr Infect Dis J</source><year>2011</year><volume>30</volume><fpage>379</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1097/INF.0b013e318202ac3a</pub-id><pub-id pub-id-type="pmid">21099445</pub-id><pub-id pub-id-type="pmcid">PMC3077445</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viscardi</surname><given-names>RM</given-names></name><name name-style="western"><surname>Kallapur</surname><given-names>SG</given-names></name></person-group><article-title>Role of Ureaplasma Respiratory Tract Colonization in Bronchopulmonary Dysplasia Pathogenesis: Current Concepts and Update</article-title><source>Clin Perinatol</source><year>2015</year><volume>42</volume><fpage>719</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.clp.2015.08.003</pub-id><pub-id pub-id-type="pmid">26593075</pub-id><pub-id pub-id-type="pmcid">PMC4662049</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glaser</surname><given-names>K</given-names></name><name name-style="western"><surname>Gradzka-Luczewska</surname><given-names>A</given-names></name><name name-style="western"><surname>Szymankiewicz-Breborowicz</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Perinatal <italic toggle="yes">Ureaplasma</italic> Exposure Is Associated With Increased Risk of Late Onset Sepsis and Imbalanced Inflammation in Preterm Infants and May Add to Lung Injury</article-title><source>Front Cell Infect Microbiol</source><year>2019</year><volume>9</volume><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2019.00068</pub-id><pub-id pub-id-type="pmid">31001484</pub-id><pub-id pub-id-type="pmcid">PMC6454044</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>EE</given-names></name><name name-style="western"><surname>Ohlsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Kellner</surname><given-names>JD</given-names></name></person-group><article-title>Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a metaanalysis</article-title><source>J Pediatr</source><year>1995</year><volume>127</volume><fpage>640</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/s0022-3476(95)70130-3</pub-id><pub-id pub-id-type="pmid">7562292</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waites</surname><given-names>KB</given-names></name><name name-style="western"><surname>Katz</surname><given-names>B</given-names></name><name name-style="western"><surname>Schelonka</surname><given-names>RL</given-names></name></person-group><article-title>Mycoplasmas and ureaplasmas as neonatal pathogens</article-title><source>Clin Microbiol Rev</source><year>2005</year><volume>18</volume><fpage>757</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1128/CMR.18.4.757-789.2005</pub-id><pub-id pub-id-type="pmid">16223956</pub-id><pub-id pub-id-type="pmcid">PMC1265909</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowe</surname><given-names>J</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>MO</given-names></name><etal>et al</etal></person-group><article-title>Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis</article-title><source>Pediatr Infect Dis J</source><year>2014</year><volume>33</volume><fpage>697</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000000239</pub-id><pub-id pub-id-type="pmid">24445836</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><etal>et al</etal></person-group><article-title>Association between <italic toggle="yes">Ureaplasma urealyticum</italic> colonization and bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis</article-title><source>Front Pediatr</source><year>2024</year><volume>12</volume><elocation-id>1436568</elocation-id><pub-id pub-id-type="doi">10.3389/fped.2024.1436568</pub-id><pub-id pub-id-type="pmid">39175806</pub-id><pub-id pub-id-type="pmcid">PMC11338929</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glaser</surname><given-names>K</given-names></name><name name-style="western"><surname>Speer</surname><given-names>CP</given-names></name></person-group><article-title>Neonatal CNS infection and inflammation caused by Ureaplasma species: rare or relevant?</article-title><source>Expert Rev Anti Infect Ther</source><year>2015</year><volume>13</volume><fpage>233</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1586/14787210.2015.999670</pub-id><pub-id pub-id-type="pmid">25578885</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silwedel</surname><given-names>C</given-names></name><name name-style="western"><surname>Speer</surname><given-names>CP</given-names></name><name name-style="western"><surname>Glaser</surname><given-names>K</given-names></name></person-group><article-title>Ureaplasma-associated prenatal, perinatal, and neonatal morbidities</article-title><source>Expert Rev Clin Immunol</source><year>2017</year><volume>13</volume><fpage>1073</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1080/1744666X.2017.1381559</pub-id><pub-id pub-id-type="pmid">28918659</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silwedel</surname><given-names>C</given-names></name><name name-style="western"><surname>Laube</surname><given-names>M</given-names></name><name name-style="western"><surname>Speer</surname><given-names>CP</given-names></name><etal>et al</etal></person-group><article-title>The Role of Ureaplasma Species in Prenatal and Postnatal Morbidity of Preterm Infants: Current Concepts</article-title><source>Neonatology</source><year>2024</year><volume>121</volume><fpage>627</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1159/000539613</pub-id><pub-id pub-id-type="pmid">38934167</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jobe</surname><given-names>AH</given-names></name><name name-style="western"><surname>Bancalari</surname><given-names>E</given-names></name></person-group><article-title>Bronchopulmonary dysplasia</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>163</volume><fpage>1723</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.163.7.2011060</pub-id><pub-id pub-id-type="pmid">11401896</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>EA</given-names></name><name name-style="western"><surname>Dysart</surname><given-names>K</given-names></name><name name-style="western"><surname>Gantz</surname><given-names>MG</given-names></name><etal>et al</etal></person-group><article-title>The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach</article-title><source>Am J Respir Crit Care Med</source><year>2019</year><volume>200</volume><fpage>751</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1164/rccm.201812-2348OC</pub-id><pub-id pub-id-type="pmid">30995069</pub-id><pub-id pub-id-type="pmcid">PMC6775872</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwab</surname><given-names>F</given-names></name><name name-style="western"><surname>Gastmeier</surname><given-names>P</given-names></name><name name-style="western"><surname>Piening</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>The step from a voluntary to a mandatory national nosocomial infection surveillance system: the influence on infection rates and surveillance effect</article-title><source>Antimicrob Resist Infect Control</source><year>2012</year><volume>1</volume><elocation-id>24</elocation-id><pub-id pub-id-type="doi">10.1186/2047-2994-1-24</pub-id><pub-id pub-id-type="pmid">22958509</pub-id><pub-id pub-id-type="pmcid">PMC3489557</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>P</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N</given-names></name></person-group><article-title>Normal Values for Cerebrospinal Fluid in Neonates: A Systematic Review</article-title><source>Neonatology</source><year>2021</year><volume>118</volume><fpage>629</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1159/000517630</pub-id><pub-id pub-id-type="pmid">34818234</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deeg</surname><given-names>KH</given-names></name><name name-style="western"><surname>Staudt</surname><given-names>F</given-names></name><name name-style="western"><surname>von Rohden</surname><given-names>L</given-names></name></person-group><article-title>Classification of intracranial hemorrhage in premature infants</article-title><source>Ultraschall Med</source><year>1999</year><volume>20</volume><fpage>165</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1055/s-1999-8898</pub-id><pub-id pub-id-type="pmid">10522360</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perlman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Risser</surname><given-names>R</given-names></name><name name-style="western"><surname>Broyles</surname><given-names>RS</given-names></name></person-group><article-title>Bilateral cystic periventricular leukomalacia in the premature infant: associated risk factors</article-title><source>Pediatrics</source><year>1996</year><volume>97</volume><fpage>822</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8657521</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>MJ</given-names></name></person-group><article-title>Neonatal necrotizing enterocolitis</article-title><source>N Engl J Med</source><year>1978</year><volume>298</volume><fpage>281</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">619275</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maier</surname><given-names>RF</given-names></name><name name-style="western"><surname>Hummler</surname><given-names>H</given-names></name><name name-style="western"><surname>Kellner</surname><given-names>U</given-names></name><etal>et al</etal></person-group><article-title>National guideline for ophthalmological screening of premature infants in Germany (S2k level, AWMF guidelines register no. 024/010, March 2020): Joint recommendation of the German Ophthalmological Society (DOG), German Retina Society (RG), Professional Association of Ophthalmologists in Germany (BVA), German Society of Pediatrics and Adolescent Medicine (DGKJ), Professional Association of Pediatricians (BVKJ), Federal Association &#8220;The Premature Infant&#8221;, Society for Neonatology and Pediatric Intensive Care Medicine (GNPI)</article-title><source>Ophthalmologie</source><year>2022</year><volume>119</volume><fpage>123</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s00347-022-01632-4</pub-id><pub-id pub-id-type="pmid">35507084</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiang</surname><given-names>MF</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>GE</given-names></name><name name-style="western"><surname>Fielder</surname><given-names>AR</given-names></name><etal>et al</etal></person-group><article-title>International Classification of Retinopathy of Prematurity, Third Edition</article-title><source>Ophthalmology</source><year>2021</year><volume>128</volume><fpage>e51</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2021.05.031</pub-id><pub-id pub-id-type="pmid">34247850</pub-id><pub-id pub-id-type="pmcid">PMC10979521</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bayley</surname><given-names>N</given-names></name></person-group><source>Bayley scales of infant development: manual</source><publisher-loc>New York</publisher-loc><year>1993</year></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bayley</surname><given-names>N</given-names></name></person-group><source>Bayley scales of infant and toddler development</source><publisher-loc>San Antonio TX</publisher-loc><publisher-name>PsychCorp</publisher-name><year>2006</year></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>S</given-names></name><name name-style="western"><surname>Bountziouka</surname><given-names>V</given-names></name><name name-style="western"><surname>Linsell</surname><given-names>L</given-names></name><etal>et al</etal></person-group><source>Parent report of children&#8217;s abilities-revised (PARCA-R) technical &amp; interpretive manual</source><publisher-name>University of Leicester</publisher-name><year>2019</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2352-4642(19)30189-0</pub-id><pub-id pub-id-type="pmid">31402196</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#246;bius</surname><given-names>N</given-names></name><name name-style="western"><surname>Brenneisen</surname><given-names>W</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Protocol for the rapid detection of the urogenital tract mollicutes and Chlamydia with concomitant LGV-(sub)typing</article-title><source>Methods Mol Biol</source><year>2012</year><volume>903</volume><fpage>235</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-937-2_15</pub-id><pub-id pub-id-type="pmid">22782822</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otgonjargal</surname><given-names>B</given-names></name><name name-style="western"><surname>Batbaatar</surname><given-names>G</given-names></name><name name-style="western"><surname>Pfeffer</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>A novel mba-based Real time PCR approach for genotyping of Ureaplasma parvum validated in a cohort of Mongolian mothers and offspring</article-title><source>Int J Med Microbiol</source><year>2018</year><volume>308</volume><fpage>865</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2018.08.001</pub-id><pub-id pub-id-type="pmid">30100523</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glaser</surname><given-names>K</given-names></name><name name-style="western"><surname>Silwedel</surname><given-names>C</given-names></name><name name-style="western"><surname>Fehrholz</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title><italic toggle="yes">Ureaplasma</italic> Species Differentially Modulate Pro- and Anti-Inflammatory Cytokine Responses in Newborn and Adult Human Monocytes Pushing the State Toward Pro-Inflammation</article-title><source>Front Cell Infect Microbiol</source><year>2017</year><volume>7</volume><elocation-id>484</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2017.00484</pub-id><pub-id pub-id-type="pmid">29234642</pub-id><pub-id pub-id-type="pmcid">PMC5712342</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glaser</surname><given-names>K</given-names></name><name name-style="western"><surname>Silwedel</surname><given-names>C</given-names></name><name name-style="western"><surname>Fehrholz</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Ureaplasma isolates stimulate pro-inflammatory CC chemokines and matrix metalloproteinase-9 in neonatal and adult monocytes</article-title><source>PLoS One</source><year>2018</year><volume>13</volume><elocation-id>e0194514</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0194514</pub-id><pub-id pub-id-type="pmid">29558521</pub-id><pub-id pub-id-type="pmcid">PMC5860755</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glaser</surname><given-names>K</given-names></name><name name-style="western"><surname>Silwedel</surname><given-names>C</given-names></name><name name-style="western"><surname>Waaga-Gasser</surname><given-names>AM</given-names></name><etal>et al</etal></person-group><article-title>Ureaplasma isolates differentially modulate growth factors and cell adhesion molecules in human neonatal and adult monocytes</article-title><source>Cytokine</source><year>2018</year><volume>105</volume><fpage>45</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2018.01.026</pub-id><pub-id pub-id-type="pmid">29455108</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasper</surname><given-names>DC</given-names></name><name name-style="western"><surname>Mechtler</surname><given-names>TP</given-names></name><name name-style="western"><surname>B&#246;hm</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>In utero exposure to Ureaplasma spp. is associated with increased rate of bronchopulmonary dysplasia and intraventricular hemorrhage in preterm infants</article-title><source>J Perinat Med</source><year>2011</year><volume>39</volume><fpage>331</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1515/jpm.2011.022</pub-id><pub-id pub-id-type="pmid">21526978</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humberg</surname><given-names>A</given-names></name><name name-style="western"><surname>H&#228;rtel</surname><given-names>C</given-names></name><name name-style="western"><surname>Rausch</surname><given-names>TK</given-names></name><etal>et al</etal></person-group><article-title>Active perinatal care of preterm infants in the German Neonatal Network</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><year>2020</year><volume>105</volume><fpage>190</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2018-316770</pub-id><pub-id pub-id-type="pmid">31248963</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowe</surname><given-names>J</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>D</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Study protocol: azithromycin therapy for chronic lung disease of prematurity (AZTEC) - a randomised, placebo-controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants</article-title><source>BMJ Open</source><year>2020</year><volume>10</volume><elocation-id>e041528</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2020-041528</pub-id><pub-id pub-id-type="pmcid">PMC7539578</pub-id><pub-id pub-id-type="pmid">33028566</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#228;rtel</surname><given-names>C</given-names></name><name name-style="western"><surname>Paul</surname><given-names>P</given-names></name><name name-style="western"><surname>Hanke</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Less invasive surfactant administration and complications of preterm birth</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>8333</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-26437-x</pub-id><pub-id pub-id-type="pmid">29844331</pub-id><pub-id pub-id-type="pmcid">PMC5974027</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jobe</surname><given-names>AJ</given-names></name></person-group><article-title>The new BPD: an arrest of lung development</article-title><source>Pediatr Res</source><year>1999</year><volume>46</volume><fpage>641</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1203/00006450-199912000-00007</pub-id><pub-id pub-id-type="pmid">10590017</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y-P</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J-M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y-Q</given-names></name><etal>et al</etal></person-group><article-title>Maternal Ureaplasma exposure during pregnancy and the risk of preterm birth and BPD: a meta-analysis</article-title><source>Arch Gynecol Obstet</source><year>2022</year><volume>306</volume><fpage>1863</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s00404-022-06491-7</pub-id><pub-id pub-id-type="pmid">35277749</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowe</surname><given-names>J</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>D</given-names></name><name name-style="western"><surname>Aboklaish</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial</article-title><source>Lancet Respir Med</source><year>2024</year><volume>12</volume><fpage>608</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(24)00079-1</pub-id><pub-id pub-id-type="pmid">38679042</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beyer</surname><given-names>D</given-names></name><name name-style="western"><surname>Proquitt&#233;</surname><given-names>H</given-names></name></person-group><article-title>EBNEO Commentary: Azithromycin therapy for prevention of chronic lung disease</article-title><source>Acta Paediatr</source><year>2025</year><volume>114</volume><fpage>1080</fpage><lpage>1</lpage><pub-id pub-id-type="doi">10.1111/apa.17564</pub-id><pub-id pub-id-type="pmid">39725801</pub-id><pub-id pub-id-type="pmcid">PMC11976114</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viscardi</surname><given-names>RM</given-names></name><name name-style="western"><surname>Hashmi</surname><given-names>N</given-names></name><name name-style="western"><surname>Gross</surname><given-names>GW</given-names></name><etal>et al</etal></person-group><article-title>Incidence of invasive ureaplasma in VLBW infants: relationship to severe intraventricular hemorrhage</article-title><source>J Perinatol</source><year>2008</year><volume>28</volume><fpage>759</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/jp.2008.98</pub-id><pub-id pub-id-type="pmid">18596706</pub-id><pub-id pub-id-type="pmcid">PMC5334544</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okogbule-Wonodi</surname><given-names>AC</given-names></name><name name-style="western"><surname>Chesko</surname><given-names>KL</given-names></name><name name-style="western"><surname>Famuyide</surname><given-names>ME</given-names></name><etal>et al</etal></person-group><article-title>Surfactant protein-A enhances ureaplasmacidal activity in vitro</article-title><source>Innate Immun</source><year>2011</year><volume>17</volume><fpage>145</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1177/1753425909360552</pub-id><pub-id pub-id-type="pmid">20197455</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>A</given-names></name><name name-style="western"><surname>Witt</surname><given-names>A</given-names></name><name name-style="western"><surname>Haiden</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>Intrauterine infection with Ureaplasma species is associated with adverse neuromotor outcome at 1 and 2 years adjusted age in preterm infants</article-title><source>J Perinat Med</source><year>2009</year><volume>37</volume><fpage>72</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1515/JPM.2009.016</pub-id><pub-id pub-id-type="pmid">18976044</pub-id></element-citation></ref></ref-list></back><sub-article id="sub-article1" article-type="aggregated-review-documents"><front-stub><title-group><article-title>Review Process File</article-title></title-group><pub-date pub-type="epub"><day>02</day><month>09</month><year>2025</year></pub-date></front-stub><body><fig id="d67e1996" position="anchor" orientation="portrait"><media xlink:href="bmjopen-2025-101442.reviewer_comments.pdf" position="float" orientation="portrait"/></fig></body></sub-article></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>